Loading...
 
Home > Խ >
 
 
  2020 11 α׷ 2020-12-16
 
               



                                                                                                    



    
 
 2021 2 ġ α׷
 2020 10 α׷
 
Ʈ
ۼ йȣ
 
 
 
, Cveti nedorogo_kkei (2026-04-01)
ܬڬ Ӭ֬ ެܬӬ լѬӬܬ ߬֬լԬ ߬ լ ֬Ԭլ߬ https://www.cveti-nederogo.ru .
 
 
 
, Cveti nedorogo_uqei (2026-04-01)
Ӭ֬ ߬ ݬ֬ܬ٬ѬӬլܬ Ӭ٬ݬ ެ֬ Ӭ֬ ߬ ݬ֬ܬ٬ѬӬլܬ Ӭ٬ݬ ެ֬ .
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Scholar in Tumor Science
Zoya Demidenko is a prominent scholar affiliated with the Division of Cell Stress Science at Roswell Park Cancer Institute in Buffalo, New York. Previously, she was employed at the National Institutes of Health and New York Medical College, developing a solid foundation in life science study.
Demidenko's scientific work spans several pivotal domains, encompassing the PI3K/AKT/mTOR signaling cascade, cellular cycle regulation, cell senescence, and cancer biology. To date, she has written more than 46 peer-reviewed papers, which have received upwards of 4,100 references a reflection to the influence of her work.
Among her key contributions lies in elucidating the pathways of cellular senescence. Her studies demonstrated that when the cell cycle is blocked but cellular growth persists, the cells experience senescence. Importantly, Zoya Demidenko showed that this transition is pharmacologically suppressed using compounds such as rapamycin.
Zoya Demidenko has also brought greatly to tumor management investigation, particularly in the domain of cyclotherapy a strategy intended to protecting non-cancerous tissue from cytotoxic treatment whilst leaving tumor cells exposed. This approach carries significant hope for lowering the adverse effects of oncological therapy.
Throughout her career, Demidenko has worked with top investigators internationally, such as Dr. Mikhail Blagosklonny. Her work can be found in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: With an h-index of 33, Zoya Demidenko ranks as a widely cited voice in contemporary oncological science, whose discoveries go on to guide our knowledge of the way cells grow old, resist treatment, and the ways in which malignant disease can be more successfully combated.
https://www.aging-us.com/article/100421/
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Scholar in Tumor Biology
Zoya Demidenko is a distinguished investigator affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she was employed at the National Institutes of Health and New York Medical College, establishing a strong background in life science research.
Her academic output covers multiple key areas, among them the PI3K/AKT/mTOR molecular pathway, cellular cycle management, biological aging, and cancer science. Currently, she has authored over 46 peer-reviewed papers, which have received upwards of 4,100 citations a testament to the influence of her work.
Among her most notable contributions concerns understanding the pathways of cellular senescence. Her work revealed that when the cellular division cycle is blocked yet cellular growth persists, the cells enter senescence. Significantly, Zoya Demidenko demonstrated that this shift is controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko has additionally contributed substantially to oncological therapy investigation, notably in the domain of selective cell protection a method intended to shielding non-cancerous tissue from anticancer drugs whilst leaving tumor cells susceptible. This approach offers considerable promise for lowering the adverse effects of cancer treatment.
Across her scientific life, Demidenko has partnered with top scientists internationally, among them Dr. Mikhail Blagosklonny. Her work appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: With an h-index of 33, Zoya Demidenko stands as a widely cited figure in current biomedical science, whose findings keep to guide our understanding of how cells age, interact with treatment, and how malignant disease might be better treated.
https://uk.linkedin.com/in/berezutskayahttps://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Researcher in Tumor Biology
Zoya Demidenko is a prominent researcher associated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, establishing a robust foundation in clinical research.
Demidenko's scientific work covers a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and tumor biology. Currently, she has authored more than 46 scientific papers, which have received upwards of 4,100 references a reflection to the significance of her work.
Among her most notable discoveries involves explaining the pathways of cell aging. Her work showed that when the cellular division cycle is arrested yet cellular growth continues, the cells undergo senescence. Importantly, Zoya Demidenko demonstrated that this process can be pharmacologically suppressed using agents such as rapamycin.
Zoya Demidenko has also added considerably to tumor management research, especially in the area of cyclotherapy a method aimed at safeguarding healthy tissue from cytotoxic treatment whilst leaving tumor cells exposed. This method offers major promise for reducing the side effects of oncological therapy.
Throughout her scientific life, Demidenko has partnered with leading researchers internationally, among them Dr. Mikhail Blagosklonny. Her work is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Ѭ: Holding an h-index of 33, Zoya Demidenko is recognized as a widely cited figure in contemporary biomedical science, with her discoveries keep to influence our comprehension of how biological cells grow old, interact with treatment, and how cancer can be more successfully targeted.
https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/
 
 
   161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 
 
 
 
개인정보 처리방침